Indian exporters of specialty pharmaceuticals and active ingredients woke up to a split U.S. tariff regime on Monday as a 100 percent Section 232 duty on patented drug imports took full effect for most companies, while a parallel Commerce Department list put orphan drugs, gene therapies and related categories on a zero rate when sourced from India and 18 other jurisdictions.
The Bureau of Industry and Security guidance, published in the Federal Register on Sept. 23, implements clause 3(d) of Presidential Proclamation 11020. It took effect for entries filed from 12:01 a.m. Eastern time on Sept. 29, the same day the broader 100 percent levy expanded beyond firms named in an earlier annex.
What qualifies at zero percent
Commerce defined eligible products to include drugs whose approved indications are designated as orphan; nuclear medicines; plasma-derived therapies; fertility drugs; cell and gene therapies; antibody-drug conjugates; medical countermeasures for chemical, biological, radiological and nuclear threats; and certain animal-health products, along with associated ingredients.
India appears on the jurisdiction list alongside the European Union, Japan, South Korea, the United Kingdom, Vietnam and others Commerce said have current or forthcoming trade and security framework agreements with the United States. Generic pharmaceuticals and their ingredients remain outside the Section 232 pharmaceutical tariffs, according to the notice.
What changed for exporters Monday
For Indian manufacturers shipping patented specialty lines to the United States, the practical question is documentation: goods must map to the listed categories and originate in an eligible jurisdiction to claim the zero rate rather than the 100 percent ad valorem duty that now applies to covered patented articles under HTSUS heading 9903.04.60.
Companies whose products do not fall under the country-based exemption may still petition Commerce at pharma232@bis.doc.gov for zero treatment if they demonstrate an urgent U.S. health need. BIS said it invoked emergency paperwork procedures because it needed time to evaluate those requests before the Sept. 29 widening.
Industry read-through in India
Trade lawyers in Mumbai said contract manufacturers with U.S. orphan-drug clients should revisit purchase orders this week to confirm whether finished doses or APIs meet the specialty definitions and whether shipment origin documentation satisfies Commerce’s jurisdiction test.
ThePrint, citing PTI, reported that Washington would not charge ad valorem tariffs on the listed specialty categories imported from India and 19 other economies, framing the move as part of Trump’s April proclamation adjusting pharmaceutical imports for national-security reasons. Indian officials have not issued a separate ministry statement since the Federal Register notice.
What to watch
Commerce warned that the eligible jurisdiction list may change in future notices. Importers face a narrow window to file urgent-health-need applications while U.S. customs begins enforcing the widened 100 percent rate on patented products from companies outside the earlier annex.
For Indian firms already facing U.S. scrutiny on quality and supply-chain transparency, the zero carve-out offers relief on niche therapies but leaves most patented small-molecule exports subject to the full Section 232 rate unless they secure a separate approval.